Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02510300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02510300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Lead sponsor
Gilead Sciences
Phase
Observational
Overall status
Terminated
Start date
October 21, 2015
Completion date
January 6, 2023
Enrollment
461 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection